| Autor: |
Lao Romera, Juan, Puertolas Hernández, Teresa, Peláez Fernández, Ignacio, Sampedro Gimeno, Teresa, Fernández Martínez, Roberto, Fernández Pérez, Isaura, Iranzo González Cruz, Vega, Illarramendi Mañas, José, Garcerá Juan, Salvador, Ciruelos Gil, Eva |
| Zdroj: |
Advances in Therapy; Sep2011, Vol. 28, p1-18, 18p |
| Abstrakt: |
Clinical trials conducted over the last two decades have demonstrated that 5 years of treatment with tamoxifen (TAM) after local treatment in postmenopausal patients with positive hormone receptor early breast cancer improves disease-free survival and overall survival. More recently, aromatase inhibitors (AI) have been tested in several randomized clinical trials in this setting. The studies have tested either AI versus TAM or different sequential approaches combining the two agents. While the most effective strategy remains to be determined, overall, incorporation of AI resulted in better disease-free survival, particularly in the worst-prognosis subgroup of patients. In addition, long-term treatment with AI was, in general, well tolerated. However, mature results are needed in order to be able to assess the effect in overall survival. The authors of this supplement paper include the key points of roundtable presentations and discussions of hormonal therapy in breast cancer by topic. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink